300765:SZSECSPC Innovation Pharmaceutical Co., Ltd. Class A Analysis
Data as of 2026-05-22 - not real-time
CN¥28.84
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The stock is trading below its 20‑day and 50‑day moving averages and well under the 200‑day average, with the RSI sitting in the mid‑30s and a bearish MACD histogram, signaling a short‑term downtrend despite a low beta that limits market‑wide volatility.
Fundamentally, the company delivers robust revenue growth yet posts negative operating and profit margins, a negative trailing EPS and modest free cash flow, while maintaining a strong cash position and minimal debt. The DCF model implies a substantial upside potential, the dividend yield is minimal and likely unsustainable, and the market sentiment index reflects extreme greed, suggesting a disconnect between price action and underlying financial health.
Fundamentally, the company delivers robust revenue growth yet posts negative operating and profit margins, a negative trailing EPS and modest free cash flow, while maintaining a strong cash position and minimal debt. The DCF model implies a substantial upside potential, the dividend yield is minimal and likely unsustainable, and the market sentiment index reflects extreme greed, suggesting a disconnect between price action and underlying financial health.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below key moving averages and near support level
- Bearish MACD and RSI indicating continued downside pressure
- High 30‑day volatility may cause erratic price swings
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong revenue growth and ample cash cushion
- Potential upside indicated by DCF and analyst price targets
- Low beta suggests limited exposure to broader market swings
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Growth trajectory in biopharmaceutical and functional food segments
- Improving profitability outlook as scale and product mix evolve
- Strategic positioning within a defensive consumer sector with long‑term demand
Key Metrics & Analysis
Financial Health
Revenue Growth40.80%
Profit Margin-13.11%
P/E Ratio35.5
ROE-16.98%
ROA-6.07%
Debt/Equity0.47
P/B Ratio15.6
Op. Cash FlowCN¥-288412736
Free Cash FlowCN¥175.5M
Technical Analysis
TrendBearish
RSI36.4
SupportCN¥28.50
ResistanceCN¥33.55
MA 20CN¥30.85
MA 50CN¥31.49
MA 200CN¥38.80
MACDBearish
VolumeStable
Fear & Greed Index90.89
Valuation
Fair ValueCN¥5.13
Target PriceCN¥49.13
Upside/Downside70.37%
GradeUndervalued
TypeGrowth
Dividend Yield0.07%
Risk Assessment
Beta0.30
Volatility41.43%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.